The safety of raloxifene has been assessed primarily in 12 Phase 2 and Phase 3 studies with placebo, estrogenand estrogen- progestin therapy control groups.
The recommended intake of vitamin D is IU daily. Moderate Raloxifene may decrease prothrombin time if coadministered wih warfarin. Your email has been sent.
Androvax androstenedione albumin Ovandrotone albumin Fecundin. Metabolism Extensively undergoes first-pass metabolism in the liver to glucuronide conjugates Metabolites: Safety and efficacy not established. Pediatric — The pharmacokinetics of raloxifene has not been evaluated in a pediatric population [see Use in Specific Populations 8. Raloxifene HCl is an off-white to pale-yellow solid that is very slightly soluble in water.
Sign Up It's Free! Among the factors included in the modified Gail model are the following: Evista should not be used by lactating women [see Contraindications 4. Triglyceride levels may increase in women with history of triglyceride elevation in response to oral estrogens. The incidence of all-cause mortality was similar among groups: The greatest risk for deep vein thrombosis and pulmonary embolism occurs during the first 4 months of treatment, and the magnitude of risk appears to be similar to the reported risk associated with use of hormone therapy.
Hepatic Impairment - The disposition of raloxifene was compared in 9 patients with mild Child-Pugh Class A hepatic impairment total bilirubin ranging from 0.
Pharmacology Mechanism of Action Selective estrogen receptor modulator; estrogenlike effects on bone decreases bone resorption; increases bone density and lipid decrease in LDL ; antiestrogenic in uterus, breast. Raloxifene undergoes extensive first-pass metabolism to the following glucuronide conjugates: When considering treatment, physicians need to discuss the potential benefits and risks of EVISTA treatment with the patient.
In terms of bone cycles, this is equivalent to approximately 6 years in humans.
What would you like to print? Last reviewed on RxList: Raloxifene is a non-steroidal selective estrogen-receptor modulator SERM which is used for prevention and treatment of postmenopausal osteoporosis.
The effect of EVISTA on the incidence of invasive breast cancer was assessed in a randomized, placebo-controlled, double-blind, multinational study in 10, postmenopausal women at increased risk of coronary events. The issue of treatment of invasive breast cancer should be referred to a specialist in most cases and therefore beyond the scope of this article.
The decrease in incidence of vertebral fracture was greater than could be accounted for by increase in BMD alone.